JP2011509295A5 - - Google Patents

Download PDF

Info

Publication number
JP2011509295A5
JP2011509295A5 JP2010542277A JP2010542277A JP2011509295A5 JP 2011509295 A5 JP2011509295 A5 JP 2011509295A5 JP 2010542277 A JP2010542277 A JP 2010542277A JP 2010542277 A JP2010542277 A JP 2010542277A JP 2011509295 A5 JP2011509295 A5 JP 2011509295A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
rasagiline
coating
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010542277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509295A (ja
JP5583597B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000134 external-priority patent/WO2009089049A1/en
Publication of JP2011509295A publication Critical patent/JP2011509295A/ja
Publication of JP2011509295A5 publication Critical patent/JP2011509295A5/ja
Application granted granted Critical
Publication of JP5583597B2 publication Critical patent/JP5583597B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010542277A 2008-01-11 2009-01-09 ラサジリン製剤、その調製および使用 Expired - Fee Related JP5583597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1086008P 2008-01-11 2008-01-11
US61/010,860 2008-01-11
PCT/US2009/000134 WO2009089049A1 (en) 2008-01-11 2009-01-09 Rasagiline formulations, their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014146160A Division JP2014237668A (ja) 2008-01-11 2014-07-16 ラサジリン製剤、その調製および使用

Publications (3)

Publication Number Publication Date
JP2011509295A JP2011509295A (ja) 2011-03-24
JP2011509295A5 true JP2011509295A5 (enExample) 2012-03-01
JP5583597B2 JP5583597B2 (ja) 2014-09-03

Family

ID=40850833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010542277A Expired - Fee Related JP5583597B2 (ja) 2008-01-11 2009-01-09 ラサジリン製剤、その調製および使用
JP2014146160A Withdrawn JP2014237668A (ja) 2008-01-11 2014-07-16 ラサジリン製剤、その調製および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014146160A Withdrawn JP2014237668A (ja) 2008-01-11 2014-07-16 ラサジリン製剤、その調製および使用

Country Status (15)

Country Link
US (1) US20090181086A1 (enExample)
EP (1) EP2234478A4 (enExample)
JP (2) JP5583597B2 (enExample)
KR (1) KR20100107028A (enExample)
CN (1) CN101909438A (enExample)
AU (1) AU2009204454B2 (enExample)
BR (1) BRPI0905680A2 (enExample)
CA (1) CA2711817A1 (enExample)
EA (1) EA201070842A1 (enExample)
IL (1) IL206136A0 (enExample)
MX (1) MX2010007601A (enExample)
NZ (1) NZ586025A (enExample)
SG (1) SG187455A1 (enExample)
WO (1) WO2009089049A1 (enExample)
ZA (1) ZA201004086B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
MX2010013875A (es) 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
AU2010341499A1 (en) 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
WO2024098098A1 (en) * 2022-11-07 2024-05-16 Natural MedTech Pty Ltd Tryptamine formulations and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
FI955979L (fi) * 1993-06-14 1995-12-13 Janssen Pharmaceutica Nv Jatkuvasti vapauttava, kalvopäällysteinen astemitsoli- ja pseudoefedriinitabletti
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP0966435B1 (en) * 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050220864A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
EP1663167A1 (en) * 2004-07-26 2006-06-07 Teva Pharmaceutical Industries Ltd Dosage forms with an enterically coated core tablet
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
MX2010013875A (es) * 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
EP2328861A2 (en) * 2008-07-11 2011-06-08 Synthon BV Polymorphs of rasagiline hydrochloride
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) * 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
CN103188933A (zh) * 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
JP2014534195A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトルアミド
EP2766004A4 (en) * 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
WO2013055687A2 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan

Similar Documents

Publication Publication Date Title
JP2011509295A5 (enExample)
RU2298402C2 (ru) Твердая лекарственная форма тербинафина для перорального введения
JP2015110604A (ja) Ｈｒｔ製剤
JP2013512250A5 (enExample)
EP2424365A1 (en) Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics
HRP20120633T1 (hr) Formulacija rasagilina s odgođenim oslobađanjem
WO2007143674A2 (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
CN109310642B (zh) 美沙拉嗪的口服药物组合物
AU2013229990B2 (en) Controlled-release solid dosage forms of mesalamine
JP2016516698A5 (enExample)
JP2012516299A (ja) 有機化合物のガレヌス製剤
JP2005503366A (ja) アリルアミン−またはベンジルアミン−抗真菌剤の被覆顆粒
CN107205950B (zh) 金刚烷胺组合物的施用方法
TW201247240A (en) Rapid dissolve tablet compositions for vaginal administration
HUP0303163A2 (hu) Tramadolalapú gyógyszerkészítmény
AU2002321249A1 (en) Pharmaceutical compositions containing terbinafin and use thereof
JP2017510607A5 (enExample)
WO2017168244A1 (en) Pharmaceutical compositons for n-propargylamine derivative
TW201739455A (zh) 菸鹼醯胺的口服醫藥組成物
JP5848432B2 (ja) ミルタザピンを含有する口腔内崩壊錠
WO2021101875A1 (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
JP2019533672A5 (enExample)
JP2013536832A (ja) ミルナシプランの制御放出医薬組成物
WO2007010930A1 (ja) 口腔内崩壊製剤用の薬物含有被覆微粒子及びその製造方法
CN102232934B (zh) 一种脉冲微丸及含其的脉冲口腔崩解片,制备方法和用途